Somatostatin Receptor Theranostics for Refractory Meningiomas

Somatostatin Receptor Theranostics for Refractory Meningiomas

Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy. The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 17...

Full description

Bibliographic Details
Main Authors: Betty Salgues, Thomas Graillon, Tatiana Horowitz, Olivier Chinot, Laetitia Padovani, David Taïeb, Eric Guedj
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Current Oncology
Subjects:
meningioma
peptide receptor radionuclide therapy
somatostatin receptor
treatment-refractory meningioma
Online Access:https://www.mdpi.com/1718-7729/29/8/438

Internet

https://www.mdpi.com/1718-7729/29/8/438

Similar Items